Drug glossary Drug

Porustobart

A drug being studied in colorectal cancer trials. It appears in 1 clinical trial.

See its trials
United States No data
European Union No data
Spain No data

What it is

Porustobart is an investigational medication currently being studied in clinical trials for certain types of colorectal cancer. Specifically, it is being investigated in adults with resectable microsatellite stable (MSS) colon cancer, meaning the cancer can be removed by surgery and is MSS (a common type of colon cancer). The trial is exploring whether giving porustobart together with another immunotherapy drug, pembrolizumab, before surgery can help treat the cancer. This approach is called neoadjuvant therapy. Researchers are looking at how well this combination works in destroying the cancer before surgery and what side effects patients might experience. The trial compares different dosing schedules of porustobart alongside pembrolizumab.

How it works

Porustobart is being studied in combination with pembrolizumab. Pembrolizumab is an immunotherapy drug that helps the body's immune system recognize and attack cancer cells. Porustobart is also believed to work by interacting with the immune system to fight cancer, although the specific details of its mechanism are still being investigated in clinical trials. The trial aims to see if this combination enhances the immune response against the cancer before surgery.

Common side effects

As porustobart is an investigational drugIts side effects are still being evaluated in ongoing clinical trials. The trial description mentions that researchers are monitoring participants for side effects related to the medicines. Common side effects associated with immunotherapy drugs like pembrolizumab can include fatigueRashDiarrheaAnd other immune-related reactions. Specific side effects related to porustobart are not yet fully known but will be closely monitored during the trial

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.